ThermoGenesis Holdings To Present At The LD Micro 12th Annual Main Event

Thursday, December 5, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

RANCHO CORDOVA, Calif., Dec. 5, 2019 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the LD Micro 12th Annual Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, California on Wednesday, December 11, at 1:20 pm PT.  

Management will also be available for one-on-one meetings with qualified investors.  Interested parties can register and request meetings through the LD Micro Conference portal or contact Rx Communications to schedule a meeting.

A live webcast of the presentation will be available on the ThermoGenesis website at https://ThermoGenesis.com/investors/news-and-events/events-webcasts. An archived replay will be available for a period of 90 days after the conference.

About ThermoGenesis Holdings, Inc.ThermoGenesis Holdings, Inc., formerly known as Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.ThermoGenesis.com. 

Company Contact: Wendy Samford916-858-5191ir@ThermoGenesis.com

Investor Contact: Paula Schwartz, Rx Communications917-322-2216pschwartz@rxir.com

Cision View original content:http://www.prnewswire.com/news-releases/thermogenesis-holdings-to-present-at-the-ld-micro-12th-annual-main-event-300969795.html

SOURCE ThermoGenesis Holdings, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store